Abbvie Stock News

AbbVie Inc. (NYSE:ABBV) traded at $131.70 at last check on Wednesday, December 22, made an upward move of 1.34% on its previous days price. Looking at the stock we see that its previous close was $129.95 and the beta (5Y monthly) reads 0.79 with the days price range being $129.145 $131.35. The company has AbbVie Inc. (NYSE: ABBV) Has Been Trading Down. What Are The Prospects For The Future? Read More »

Parallel Advisors LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,339 shares of the companys stock after buying an additional 187 shares during the quarter. Parallel Advisors LLCs holdings in AbbVie were []

Burleson & Company LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 33,111 shares of the companys stock after selling 1,249 shares during the quarter. Burleson & Company LLCs holdings in AbbVie []

Earlier this year, AbbVie Inc. and AbbVie Biotechnology Ltd. filed a Complaint against Alvotech hf. in the US District Court for the Northern District of Illinois alleging theft of trade secrets relating to adalimumab. In October, AbbVies complaint was dismissed for lack of personal jurisdiction. AbbVie has appealed that ruling. By: Goodwin

Miracle Mile Advisors LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 91.4% in the third quarter, Holdings Channel.com reports. The firm owned 12,801 shares of the companys stock after acquiring an additional 6,114 shares during the period. Miracle Mile Advisors LLCs holdings in AbbVie were worth $1,381,000 as of its most recent []

The global Prostate Cancer Drugs market was valued at 612.86 Million USD in 2020 and will grow with a CAGR of 6.47% from 2021 to 2027. The prostate cancer drugs market comprises different medications utilized for the anticipation and therapy

A market study Global Nanoemulsion Market examines the performance of the Nanoemulsion market 2022. It encloses an in-depth analysis of the Nanoemulsion market state and the competitive landscape globally. Nanoemulsion report analyzes the prospect of Nanoemulsion market in the present

ACG Wealth decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,058 shares of the company’s stock after selling 447 shares during the quarter. ACG Wealth’s holdings in AbbVie were worth […]

Danda Trouve Investment Management Inc. reduced its position in AbbVie Inc. (NYSE:ABBV) by 18.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 431 shares of the companys stock after selling 100 shares during the period. Danda Trouve Investment Management Inc.s holdings in AbbVie were worth $46,000 at []

First Interstate Bank boosted its holdings in AbbVie Inc. (NYSE:ABBV) by 5.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,400 shares of the companys stock after purchasing an additional 122 shares during the quarter. First Interstate Banks holdings []

AbbVie Inc. (NYSE:ABBV) has received an average recommendation of Buy from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock []

XML Financial LLC raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 625.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,442 shares of the companys stock after buying an additional 43,492 shares during the period. XML Financial LLCs holdings []

Twin Capital Management Inc. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 14.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,744 shares of the companys stock after selling 4,700 shares during the period. Twin Capital Management Inc.s holdings in AbbVie []

Goelzer Investment Management Inc. decreased its position in AbbVie Inc. (NYSE:ABBV) by 1.8% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 44,574 shares of the companys stock after selling 821 shares during the period. Goelzer Investment Management Inc.s holdings in AbbVie were worth $4,808,000 at the end of the most recent quarter. []

AbbVie Inc. (NYSE:ABBV) EVP Jeffrey Ryan Stewart sold 2,152 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $128.00, for a total transaction of $275,456.00. The sale was disclosed in a document filed with the SEC, which is accessible through this []